Lisata Therapeutics, Inc. - Common Stock (LSTA)

Lisata said that it has entered into a binding term sheet under which the two companies agreed to negotiate in good faith and enter into a customary purchase agreement.

Lisata Therapeutics reported a narrower-than-expected Q3 2025 loss, advancing its lead candidate, certepetide, with a cash runway into 2027.

Companies Reporting Before The Bell • Frontline (NYSE:FRO) is expected to report quarterly earnings at $0.46 per share on revenue of $276.19 million.

LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.

Haystack Oncology, a Quest Diagnostics company, and Lisata Therapeutics collaborate to use Haystack MRD technology in a study of certepetide plus chemotherapy for metastatic pancreatic cancer, focusing on detecting circulating tumor DNA.

Lisata Therapeutics gets 2024 off to a strong start as it prepares for crucial ASCEND trial results

LSTA stock results show that Lisata Therapeutics beat analyst estimates for earnings per share the first quarter of 2024.

Companies Reporting Before The Bell • Creative Realities (NASDAQ:CREX) is estimated to report quarterly loss at $0.12 per share on revenue of $10.80 million.

Companies Reporting Before The Bell • Safe & Green Holdings (NASDAQ:SGBX) is likely to report quarterly loss at $0.23 per share on revenue of $6.88 million.